Orange Book product · Generic (ANDA)
SEVELAMER CARBONATE
SEVELAMER CARBONATE
At a glance
Feb 27, 2025
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 27, 2025
1 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
SEVELAMER CARBONATE
Strength
2.4GM/PACKET
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
Not listed
Application
ANDA 215909
Product number
002
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of SEVELAMER CARBONATE
- 2009RENVELABrand (NDA)
NDA 022318 · GENZYME
- 2007RENVELABrand (NDA)
NDA 022127 · SANOFI
- 2025SEVELAMER CARBONATEGeneric (ANDA)
ANDA 219931 · NAVINTA LLC
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 215998 · SHANDONG XINHUA
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 206234 · INVAGEN PHARMS
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 211915 · STRIDES PHARMA
- 2024SEVELAMER CARBONATEGeneric (ANDA)
ANDA 207291 · MACLEODS PHARMS LTD
- 2023SEVELAMER CARBONATEGeneric (ANDA)
ANDA 211917 · STRIDES PHARMA INTL
- 2023SEVELAMER CARBONATEGeneric (ANDA)
ANDA 206100 · MACLEODS PHARMS LTD
- 2023SEVELAMER CARBONATEGeneric (ANDA)
ANDA 217319 · CHARTWELL RX
- 2022SEVELAMER CARBONATEGeneric (ANDA)
ANDA 215537 · MICRO LABS
- 2021SEVELAMER CARBONATEGeneric (ANDA)
ANDA 201513 · LUPIN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

